Zelira Therapeutics Ltd has released a press release.
Zelira Phase 1 Chronic Pain Trial Meets Clinical Endpoints
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- TasAlk to Manufacture Zeliras Insomnia and HOPE products
- March 2020 Quarterly Report
- Insomnia Trial Meets Primary and Secondary Endpoints
- Appendix 4D & FY20 Interim Financial Report
- Phase 1 Opioid Reduction Clinical Trial Fully Enrolled
Later from Zelira Therapeutics
- Zelira Enters Deal to Develop Products For Vascular Diseases
- June 2020 Quarterly Report
- ZLD Successfully Completes $8.75M Oversubscribed Placement
- HOPE Range Of Products Launches In Louisiana
- Appendix 4E & Financial Statements
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics